ALKERMES | ALKS - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.63B 54M 2026-06
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.72B 134M 2026-06
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.25B 168M 2026-09
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 2.86B 25M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Otsuka Holdings JPY 274.44B 14.95B 2026-06
Ovoca Bio EUR 617K 15K 2025-12
Pfizer USD 3.41B 496M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06